Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Sugemalimab Injection

This drug is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer who are negative for epidermal growth factor receptor (EGFR) gene mutation and negative for anaplastic lymphoma kinase (ALK) in combination with pemetrexed and carboplatin, and for the first-line treatment of patients with metastatic squamous non-small cell lung cancer in combination with paclitaxel and carboplatin. [1]
Sugemalimab injection is a recombinant anti-PD-L1 fully human monoclonal antibody that can block the interaction between PD-L1 and PD-1 on T cells and CD80 on immune cells, and exerts anti-tumor effects by eliminating the immunosuppressive effect of PD-L1 on cytotoxic T cells. The launch of this product provides patients with a new treatment option.

Share: